Celgene's multiple myeloma drug Pomalyst wins FDA approval

02/10/2013 | HealthDay News · Reuters

The FDA has approved Celgene's Pomalyst, or pomalidomide, as treatment for patients with multiple myeloma who have stopped responding to other therapies. Pomalyst is intended to strengthen the immune system in blocking and eliminating cancer cells. The drug's label will include a warning that it can cause clots and that it should not be used by pregnant women because of the risk for birth defects.

View Full Article in:

HealthDay News · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA